A patient-specific therapeutic cancer peptide vaccine composed of synthetic peptides representing tumor-specific somatic mutations selected via whole-exome/RNA sequencing and HLA typing to generate high-affinity HLA-binding peptides. Designed to prime and expand neoantigen-specific CD8+ and CD4+ T cells via dendritic cell antigen presentation, enabling recognition and killing of tumor cells expressing the targeted neoantigens.
Patient-specific synthetic neoantigen peptides are selected by tumor sequencing and HLA typing and administered to be taken up and presented by antigen-presenting cells (HLA class I/II). This primes and expands neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells, enabling immune recognition and killing of tumor cells expressing the targeted mutations.
NO
INDIRECT
The vaccine induces neoantigen-specific CD8+ T cells that kill cells presenting the tumor-derived peptide in HLA class I (e.g., HLA-C) via perforin/granzyme or Fas-FasL. HLA-C itself is not the cytotoxic target.
A patient-specific therapeutic cancer peptide vaccine composed of synthetic peptides representing tumor-specific somatic mutations selected via whole-exome/RNA sequencing and HLA typing to generate high-affinity HLA-binding peptides. Designed to prime and expand neoantigen-specific CD8+ and CD4+ T cells via dendritic cell antigen presentation, enabling recognition and killing of tumor cells expressing the targeted neoantigens.
Patient-specific synthetic neoantigen peptides are selected by tumor sequencing and HLA typing and administered to be taken up and presented by antigen-presenting cells (HLA class I/II). This primes and expands neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells, enabling immune recognition and killing of tumor cells expressing the targeted mutations.
NO
INDIRECT
The vaccine primes endogenous T cells against tumor-specific neoantigen peptides; CD8+ T cells then kill tumor cells presenting those peptides on HLA. HLA-DRA is part of antigen presentation on APCs and is not a killing target.
Rabbit polyclonal antilymphocyte globulin used for in vivo T-cell depletion to reduce graft-versus-host disease risk.
Rabbit polyclonal IgG against multiple human T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, HLA) that depletes T lymphocytes via complement-dependent cytotoxicity, Fc-mediated ADCC/phagocytosis, and apoptosis, producing in vivo T‑cell immunosuppression to reduce GVHD risk.
YES
DIRECT
rATG contains antibodies that bind T‑cell antigens including CD11a, opsonizing these cells and inducing complement-dependent lysis and Fc receptor–mediated ADCC/phagocytosis, leading to apoptosis and depletion.
A patient-specific therapeutic cancer peptide vaccine composed of synthetic peptides representing tumor-specific somatic mutations selected via whole-exome/RNA sequencing and HLA typing to generate high-affinity HLA-binding peptides. Designed to prime and expand neoantigen-specific CD8+ and CD4+ T cells via dendritic cell antigen presentation, enabling recognition and killing of tumor cells expressing the targeted neoantigens.
Patient-specific synthetic neoantigen peptides are selected by tumor sequencing and HLA typing and administered to be taken up and presented by antigen-presenting cells (HLA class I/II). This primes and expands neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells, enabling immune recognition and killing of tumor cells expressing the targeted mutations.
NO
INDIRECT
Peptide vaccine antigens are presented on HLA-DR of APCs to prime T cells; the resulting effector T cells kill tumor cells presenting the neoantigen peptides (primarily on HLA class I, sometimes class II). HLA-DRB1-expressing cells are not themselves targeted for killing.
A patient-specific therapeutic cancer peptide vaccine composed of synthetic peptides representing tumor-specific somatic mutations selected via whole-exome/RNA sequencing and HLA typing to generate high-affinity HLA-binding peptides. Designed to prime and expand neoantigen-specific CD8+ and CD4+ T cells via dendritic cell antigen presentation, enabling recognition and killing of tumor cells expressing the targeted neoantigens.
Patient-specific synthetic neoantigen peptides are selected by tumor sequencing and HLA typing and administered to be taken up and presented by antigen-presenting cells (HLA class I/II). This primes and expands neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells, enabling immune recognition and killing of tumor cells expressing the targeted mutations.
NO
INDIRECT
The vaccine primes neoantigen-specific T cells; activated CTLs then kill tumor cells presenting the mutant peptides on HLA (perforin/granzyme apoptosis). HLA-DQA1 is only involved in antigen presentation and is not a cytotoxic target.